Tomoko Ogawa-Morita

Tomoko Ogawa-Morita

Auto-generated profile, based on publicly available information

Tomoko Ogawa-Morita

Division of Pharmacy, National Cancer Center Hospital East, Chiba, Japan

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2015 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
TMTomoko O Morita
Tomoko O Morita
AYAyumi Yamaguchi
Ayumi Yamaguchi
SKSadaaki Kimura
Sadaaki Kimura
HFHirofumi Fujii
Hirofumi Fujii
KEKazushi Endo
Kazushi Endo
HMHironobu Minami
Hironobu Minami
Purpose: A simple suspension method has been developed for tube administration, in which tablets (and capsules) are disintegrated in hot water (55℃) without grinding (or opening) them. In the present study, we evaluated the feasibility of this simple suspension method for the preparation of lenalidomide (Celgene, Summit, New Jersey and USA) suspension by testing the stability of this drug at 55℃ and its adsorbability on the tube. Methods: We examined, by high-performance liquid chromatography, the time-dependent changes in the concentration of lenalidomide in suspensions of the drug prepared by the simple suspension method. The high-performance liquid chromatography analyses of lenalidomide were performed on Prominence LC-20AB/SPD-20 A (Shimadzu, Kyoto, Japan) with a ZORBAX SB-C18 RR analytical column (Agilent Technologies, Santa Clara, California, USA; particle size: 2.1 × 100 mm, 3.5 µm) at a flow rate of 0.4 mL/min. A solvent system consisting of 10 mM ammonium acetate (pH 7.0)/acetonitrile was used as the eluent and the eluate was detected by UV at 254 nm. Results: Lenalidomide was confirmed to remain stable in hot water at 55℃ for 24 h in the prepared suspension by the simple suspension method, and more than 99% of the drug could be recovered from the suspension. In addition, 94.5–98.0% of the drug amount could pass through a percutaneous endoscopic gastrostomy tube. Lenalidomide was scarcely adsorbed on to the percutaneous endoscopic gastrostomy tube made of polyurethane or polyvinyl chloride. Conclusion: Lenalidomide was found to be stable even in hot water and was not adsorbed on to the percutaneous endoscopic gastrostomy tube.

7 June 2017 in International Journal of Analytical Chemistry
Verified
Journal Article
Open access
PDF file
TOTomoko Ogawa-Morita
Tomoko Ogawa-Morita
YSYoshiyuki Sano
Yoshiyuki Sano
TOTomoka Okano
Tomoka Okano
HFHirofumi Fujii
Hirofumi Fujii
MTMakoto Tahara
Makoto Tahara
HMHironobu Minami
Hironobu Minami
Toward conducting clinical pharmacokinetic studies of an antineoplastic agent, lenvatinib, we developed a liquid chromatography-tandem mass spectrometric assay for its quantitative analysis in human plasma. Analyte (lenvatinib) and internal standard (IS, propranolol) in the plasma were extracted by using acetonitrile and chromatographically separated by using a XTerra MS C18 column with 0.2 mL/min flow and mobile phase starting with 0.1% formic acid in water, followed by increasing percentage of acetonitrile. Detection was performed by using combined reversed-phase liquid chromatography-tandem mass spectrometry (LC/MS-MS) with positive ion electrospray ionization. MS-MS ion transitions used were 427.602>371.000 for lenvatinib and 260.064>116.005 for IS. This study was validated for accuracy, precision, linearity, range, selectivity, lower limit of quantification, recovery, and matrix effect according to the Guideline on Bioanalytical Method Validation in Pharmaceutical Development in Japan. Calibration curve was plotted by using lenvatinib concentrations ranging within 9.6–200 ng/mL, and correlation coefficients (r2) were in excess of 0.997. Intra- and interday accuracy ranged within 95.8–108.3% with mean recoveries of 66.8% for lenvatinib, and precision was <6.7% at all quality control concentration levels. Matrix effect analysis showed extraction efficiency of 15.7% for lenvatinib. Collectively, these findings demonstrate the feasibility of this method to evaluate kinetic disposition of lenvatinib.

19 September 2020 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
TMTomoko Morita-Ogawa
Tomoko Morita-Ogawa
HSHiroki Sugita
Hiroki Sugita
HMHironobu Minami
Hironobu Minami
TYTakuhiro Yamaguchi
Takuhiro Yamaguchi
KHKazuhiko Hanada
Kazuhiko Hanada

5 October 2012 in International Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
TOTomoko Ogawa
Tomoko Ogawa
SNSeiji Niho
Seiji Niho
SNShunji Nagai
Shunji Nagai
TKTakashi Kojima
Takashi Kojima
YNYoshiko Nishimura
Yoshiko Nishimura
Hironobu MinamiHironobu Minami
Hironobu Minami

23 August 2022 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
TMTomoko O. Morita
Tomoko O. Morita
KHKazuhiko Hanada
Kazuhiko Hanada